0000899243-22-038538.txt : 20221214
0000899243-22-038538.hdr.sgml : 20221214
20221214215016
ACCESSION NUMBER: 0000899243-22-038538
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221212
FILED AS OF DATE: 20221214
DATE AS OF CHANGE: 20221214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ciaramella Giuseppe
CENTRAL INDEX KEY: 0001786322
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39208
FILM NUMBER: 221463542
MAIL ADDRESS:
STREET 1: C/O BEAM THERAPEUTICS INC.
STREET 2: 26 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Beam Therapeutics Inc.
CENTRAL INDEX KEY: 0001745999
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 26 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-327-8775
MAIL ADDRESS:
STREET 1: 26 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-12-12
0
0001745999
Beam Therapeutics Inc.
BEAM
0001786322
Ciaramella Giuseppe
C/O BEAM THERAPEUTICS INC.,
238 MAIN STREET
CAMBRIDGE
MA
02142
0
1
0
0
President & CSO
Common Stock
2022-12-12
4
M
0
18211
0.67
A
133825
D
Common Stock
2022-12-12
4
M
0
8652
4.22
A
142477
D
Common Stock
2022-12-12
4
S
0
31699
42.30
D
110778
D
Common Stock
2022-12-12
4
S
0
13933
43.15
D
96845
D
Common Stock
2022-12-12
4
S
0
5383
43.87
D
91462
D
Stock Option (Right to Buy)
0.67
2022-12-12
4
M
0
18211
0.00
D
2028-05-08
Common Stock
18211
189491
D
Stock Option (Right to Buy)
4.22
2022-12-12
4
M
0
8652
0.00
D
2029-02-13
Common Stock
8652
4326
D
The stock option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Each sale price reported is a weighted average price. The Reporting Person undertakes to provide Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.74 to $44.06, inclusive.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.74 to $42.71, inclusive.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.76 to $43.75, inclusive.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.76 to $44.06, inclusive.
25% of the shares subject to the stock option vested on the first anniversary of the vesting commencement date, February 26, 2018, and the remaining shares vested in 36 substantially equal monthly installments thereafter.
The option award vests upon the achievement of a closing price hurdle following BEAM's initial public offering (which closing price hurdle has been achieved) in three equal installments on December 21, 2021, June 30, 2022 and December 31, 2022.
By: /s/ Christine Bellon, Attorney-in-fact
2022-12-14